Tanox Completes Enrollment of TNX-355 Phase II Trial to Treat HIV

Tanox has completed enrollment in its Phase II clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).

The study, which has enrolled the target of 80 patients, is being conducted at 30 sites in the U.S., Canada and Puerto Rico. The Phase II study is a three-arm, double-blind, placebo-controlled study evaluating the safety and efficacy of TNX-355, as assessed by viral load reduction.

The study compares the effects of two different dosages of TNX-355 added to optimized background therapy (OBT) with the effect of OBT plus placebo in treatment-experienced, HIV-1 infected patients who have failed highly active antiretroviral therapy.